NCT06142357

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

Prospective Observational Study With Retrospective Part to Evaluate Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Moderate-to-severe Plaque Psoriasis

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 199 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 6 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

Multicenter, non-interventional, cohort study in pediatric patients with moderate to severe plaque-type psoriasis. Retrospective data collection is planned at patients' inclusion.

Detailed description

This observational study will be performed at healthcare facilities treating pediatric psoriasis patients. The study population will consist of a representative group of pediatric patients with moderate-to-severe plaque psoriasis for whom routine treatment with secukinumab according to the approved national label is initiated during 4 to 16 weeks Retrospective data collection is planned at patients' inclusion. Prospective data collection will continue during follow-up routine visits until secukinumab discontinuation or maximum duration of follow-up for 104 weeks after index date.

Conditions

• Moderate-to-severe Plaque Psoriasis

Interventions

Type	Name	Description
OTHER	Secukinumab	There is no treatment allocation. Patients administered secukinumab by prescription will be enrolled

Timeline

• Start date: 2023-12-29
• Primary completion: 2027-08-31
• Completion: 2027-08-31
• First posted: 2023-11-21
• Last updated: 2025-12-24

Locations

16 sites across 1 country: Russia